COVID-19

Emory University: COVID-19 Updates for the Emory Community

• July 8: Community Health and Safety during Return to Campus for Research
• June 16: MEMORANDUM: Phase 2 Resumption of Research: Lifting the suspension of travel for faculty
• May 29: Updates from Laney Gradate School - Return to Research at Lower Density
• May 26: Return to Research at Lower Density
• May 22: Updates from Laney- Return to campus for research framework
• May 18: Laney - Return to campus for research framework
• May 15: Resumption of Research -- Plan for Phased Return to Campus

DAR: COVID-19 Updates

• DAR 2020-08: COVID-19: DAR Resource Scheduling and New User Access
• DAR 2020-07: COVID-19 DAR Badge Access Information
• DAR 2020-06: COVID-19: DAR Facility Access and Required Training (PDF)
• DAR 2020-05: COVID-19: Research Expansion in the DAR, Phase 1 (PDF)

EHSO

• Return to Laboratory Research at Lower Density Checklist (PDF)

IRB: COVID-19 Guidance

• Emory IRB Guidelines: Resuming Non-Essential In-Person Human Subjects Research

Faculty and Staff

• For Faculty and Staff looking for help with childcare in the time of COVID
  • Previous Live Q&A:
    • Wed, Sept. 2 @ 7pm
    • Wed, Sept. 9 @ 12pm

• Emory Research COVID-19 Guidance (PDF)
• Research Continuity at Emory University FAQs (PDF)
• Emory University Essential Research Request (PDF)
• Checklist to Ramp Down Non-Essential Laboratory Research (PDF)
• Emory Research Slowdown Planning Tool (PDF)
• Recommendations for the Management of Clinical Trials during COVID-19 Pandemic (PDF)
• Guidance for Managing Emory University Research Enterprise During COVID-19
• Emory Integrated Core Facilities - Cryopreservation of Essential Mouse Lines (PDF)
• Researcher Guidance COVID-19 and IRB Review (PDF)
• EICF 2020-01: COVID-19 Core Core Facilities (PDF) Operations Update
• DAR 2020-01: COVID-19 Animal Preservation Measure 1 (PDF)
• DAR 2020-03: COVID-19 DAR Phase 2 Operations (PDF)
• DAR 2020-04: COVID 19 Revised Personal Protective Equipment (PPE) Guidance (PDF)
• Winship Cancer Institute:  COVID-19 Lab Etiquette (PDF)
• COVID-19 Coverage Data Collection Initiative FAQs (PDF)
• Disinfection Guidance for Laboratories and Workspaces (updated) (PDF)
• Personal Protective Equipment (PPE) and Disinfection Matrix for Emory University Employees (PDF)

• Guidance for LGS Student Research & Academic Progress
• Student Employment and COIVD-19 FAQs (PDF)

• Emory Community: Coronavirus updates
• ORA Response to the Coronavirus (COVID-19) - March 10, 2020 (PDF)

Important point on medications from Governor Kemp's briefing on March 23, 2020, signs Executive Order

All licensed Georgia pharmacists are now permitted to dispense a ninety-day supply of a prescription drug if a patient has no remaining refills and the pharmacist cannot get in contact with the prescribing provider. Pharmacists may also dispense early refills for prescription drugs. However, these authorizations do not apply to Schedule II controlled substances.

Emory University

• Exercise, Nutrition, Stress and Sleep
• Recreation & Wellness: Stay Active From Anywhere (PDF)
• Virtual Walking On Wednesdays Registration
• Blomeyer Virtual Fitness Programs (PDF)
• CBCT Response to COVID-19 - Daily Meditation
• Mental Health & COVID-19
• Coping with COVID-19
• Emotional Support During COVID-19

Centers for Disease Control and Prevention

• CDC - Handwashing: Clean Hands Save Lives
• CDC COVID-19 Updates
• CDC COVID-19 Travel Advisory
• COVID-19 Prevention & Treatment

Journal of the American Medical Association

• Wearing masks to limit the spread of COVID-19

National Institute of Environmental Health Sciences

• NIEHS COVID-19 Response Training Tool: Protecting Yourself from COVID-19 in the Workplace (PDF)

• WHO Website: Coronavirus Disease (COVID-19) Outbreak

Other Resources

• That Discomfort You're Feeling Is Grief (PDF)
• COVID-19 Global Cases

Please check back for updates.

Thursdays at Three (T@3)

Thursdays at Three (T@3) (previously known as Fridays at Four) is a bi-monthly virtual research webinar series to keep faculty engaged and updated on research topics and operations.

• April 8: Changes to the NIH Biosketch and Other Support
• March 18: NIH UNITE Initiatives
• March 4: Global Research at Emory
• February 18: Emory Faculty Making History
• February 4: Available Research Databases
• January 21: NIH FY2021 Research Budget: Emory's Approach to Engaging with NIH
• January 7: Research Administration and Process Improvement - A Path to Excellence
• December 17: Grant Writing Strategies: Funding Opportunities and How to Target the Right Agency/Organization
• November 20: Race Equity and Social Justice Research Opportunities
• November 5: Back by Popular Demand: Juggling Parenting and Research Productivity during the Pandemic
• October 15:The Future of Data Science in the Life Sciences
• October 1: The Continuing Pandemic's Impact on Your Research: Q&A with Administration
• June 5: Maintaining Global Research Productivity in the Time of a Pandemic
• May 22: The Strategy and Logistics of Ramping Up Research
• May 15: Coping Strategies for Research During COVID-19
• May 8: Emory Advocacy and Federal Legislation for Research Support in the Time of COVID-19
• May 1: Does the COVID-19 Pandemic Disproportionately Disadvantage Female Faculty Research?
• April 24: Pivoting Existing Research to COVID-19
• April 17: Ask ORA about Managing Grants, Contracts, and IRB/IACUC Reviews During the Pandemic
• April 10: Ramping Up of COVID-19 Clinical Research & Ramping Down of Other Clinical Research
• April 3: Research Productivity Related to Animal Research
• March 27: Maintaining Research Continuity During Laboratory and Human Subjects Accrual Slow-down/Shut Down
• March 20: Essential Research and Winding-down of Non-essential Research during the COVID 19 Pandemic
• March 16: Research Business Continuity during the COVID 19 Pandemic

Nell Hodgson Woodruff School of Nursing

• April 29: Faculty Forum

Office for Clinical Research

• March 27: RN and CRC COVID-19 Webinar

Office of the Senior Vice President for Research

• June 18: Juggling Parenting and Research Productivity in the Time of COVID-19

Rollins School of Public Health

• April 27: Diabetes And COVID-19: What Can The US and India Learn from Each Other?

Georgia Clinical & Translational Science Alliance

• April 16: Managing Clinical Trainees During This Time
• March 31: Ramping Down Clinical Trials

National Council of University Research Administrators

• April 8: Part 2- Research Administration in a Time of Disruption: The Impact of COVID-19 on University Research Environment and Management
• March 26: Part 1- Research Administration in a Time of Disruption: The Impact of COVID-19 on University Research Environment and Management

National Institutes of Health

• May 6: Francis Collins: Home Edition Episode 9: Eliseo Pérez-Stable on COVID-19 Health Disparities
• March 19: Special OLAW Webinar: Pandemic Contingency Planning and Its Impact on Animal Care

• Experimental Drug Out of Emory University to be Tried Against Coronavirus - March 23rd
• U.S. CDC, Emory University Set Up Sites to Check Coronavirus Symptoms Online - March 20th

The Office of Research Administration has been compiling as much information as possible on impacts to sponsored research from COVID-19. ORA will continue to update this page with information as we receive it from each agency. In addition, we have compiled a list of Frequently Asked Questions (PDF) related to sponsored research. As we receive more questions, and answers, we will continue to update the list.

Agency for Healthcare Research and Quality (AHRQ)

Flexibilities Available to AHRQ Recipients and Applicants Directly Impacted by the Novel Coronavirus (COVID-19) Due to Loss of Operations

American Cancer Society

COVID-19 and 2020 ACS Grants

American Heart Association

Centers for Disease Control and Prevention

Resources from the CDC include:

• Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
• Guidance for Institutions of Higher Education (IHEs)

Council on Governmental Relations

• Federal Agency Guidance Matrix – compilation of guidance from multiple federal agencies (Excel file)
• The Council on Governmental Relations has compiled an FAQ Regarding COVID-19’s Impact on Federal awards.

Department of Defense

• United States Army Medical Research Acquisition Activity (USAMRRA) FAQs (PDF)
• DOD Research Proposers and Awardees Impacted FAQs

Hanover Research

Grants Calendar: COVID-19 Funding

Health Resources & Services Administration (HRSA)

Novel Coronavirus (COVID-19) Frequently Asked Questions

National Cancer Institute

• Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19)
• NCI Funding during the COVID-19 Public Health Emergency

National Institutes of Health

NIH Website: Coronavirus Disease 2019 (COVID-19)

Resources from NIH include:

• Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding
• NIA Late Application Policy for NIA-Specific FOAs with Application Due Dates in May, June, and July
• NIH Late Application Policy for Institutional Training Grants to PA-20-142 and PA-20-162 Due to Public Health Emergency for United States Coronavirus Disease 2019 (COVID-19)
• NIGMS Late Application Policy for NIGMS-Specific FOAs with Application Due Dates in May 2020
• National Institute of Aging FAQ on COVID-19 Supplements
• Responding to Frequent Questions on Flexibilities Related to NIH Funding and COVID-19
• Guidance for NIH-funded Clinical Trials and Human Subjects Studies Affected by COVID-19
• Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19
  • COVID-19 Flexibilities for Applicants and Recipient FAQs
• Interim Guidance for Patients on Clinical Trials Supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP) [PDF]
• General Frequently Asked Questions (FAQs) - Proposal Submission and Award Management Related to COVID-19
• NIH LATE APPLICATION POLICY Due to Public Health Emergency for United States for 2019 Novel Coronavirus (COVID-19)
• Flexibilities for Assured Institutions for Activities of Institutional Animal Care and Use Committees (IACUCs) Due to COVID-19
• NIH Office of Laboratory Animal Welfare Disaster Planning and Response Resources
• NIH Extramural Response to Natural Disasters and Other Emergencies
• NIH Guidance on Travel and Meetings

National Science Foundation

The National Science Foundation has developed a new website for the research community with their detailed guidance on COVID-19, including Frequently Asked Questions. Of interest, NSF has confirmed that they will continue to accept proposal submissions and adhere to currently stated deadlines.

NSF Implementation of OMB Memorandum M-20-17, entitled, "Administrative Relief for Recipients and Applicants of Federal Financial Assistance Directly Impacted by the Novel Coronavirus (COVID-19) due to Loss of Operations" dated March 19, 2020

Sponsor-specific Information from Additional Sponsors

• Cystic Fibrosis Foundation - COVID-19 FAQs for Applicants and Awardees
• John Templeton Foundation - A Message to Our Grantees and Applicants on COVID-19 (PDF)

Ex Libris Pivot & Research Professional

Select Research Funding Opportunities related to Coronavirus (COVID-19) (PDF)

Georgia CTSA Weekly eRoundup

Funding & Related Information

GrantForward

• COVID-19/Coronavirus Related Funding Opportunities
  • (GrantForward Tutorial For Researchers: Search for Grants)

LifeArc

UK-based Nonprofit Funding

National Center for Advancing Translational Sciences

• Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)
• Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

National Institute for Health Research

National Institute of Allergy and Infectious Diseases

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

National Institute of Biomedical Imaging and Bioengineering

Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing

National Institute of General Medical Sciences

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

National Institute on Drug Abuse

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

National Institutes of Health

• NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional)
• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
• Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
• Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
• Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations 
• Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21 Clinical Trial Not Allowed)
• Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement -  Clinical Trial Optional)
• Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)

National Institute on Aging

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

National Institute of Mental Health

Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19

National Institute on Minority Health and Health Disparities

Notice of Intent to Publish a Funding Opportunity Announcement for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)

National Science Foundation

• Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)
• Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)

Office of Behavioral and Social Sciences Research

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences

Patient-Centered Outcomes Research Institute

Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2020

System for Award Management

• Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
• Centers for Disease Control COVID-19 Broad Agency Announcement
• 2020 NIAID Omnibus Broad Agency Announcement

University of Texas at Austin

Open Call Grant and Award Opportunities

Amazon Web Services for Coronavirus Research

Emory’s Amazon Web Services (AWS) partners informed OIT that the AWS Disaster Response Program is coordinating across AWS to identify organizations, customers, and partners active in gene sequencing, diagnostics, epidemic modeling, vaccine development, treatment development, and monitoring & evaluation for Novel Coronavirus (nCoV) for immediate and long-term engagement.

In many cases, they will provide promotional AWS utilization credits for Cloud-based research toward the Coronavirus and they are available to help submit cases for credits. OIt is available to help researchers onboard and navigate AWS in the Emory Cloud computing environment.

If anyone is interested, please contact OIT at aws.help@emory.edu.

Digital Science Dimensions

Dimensions is updated once every 24 hours, so the latest research can be viewed alongside existing information. With its range of research outputs including datasets and clinical trials, both of which are just as important as journal articles in the face of a potential pandemic, Dimensions is a one-stop shop for all COVID-19 related information. More information from Digital-Science.com

Extreme Science and Engineering Discovery Environment

XSEDE’s HPC-COVID19 Consortium, charged with meeting the high-performance computing needs of COVID19-related data analytics, simulation, bioinformatics, drug design and repurposing, and other applications.

Nature Research Microbiology Community

A weekly review of the latest SARS-CoV-2 and COVID-19 literature. More information on the Nature Microbiology Community.

Emory University - Human Resources

• Child Care During COVID-19

National Educational Services

• Long Term Care Insurance - Information Request

Security Awareness

• Defending Against COVID-19 Cyber Scams
• Best Practices for Telecommuting Securely (PDF)

Quick Guide

• Quick Start Guide to Working Remotely (PDF)

Important point on medications from Governor Kemp's briefing on March 23, 2020, signs Executive Order

All licensed Georgia pharmacists are now permitted to dispense a ninety-day supply of a prescription drug if a patient has no remaining refills and the pharmacist cannot get in contact with the prescribing provider. Pharmacists may also dispense early refills for prescription drugs. However, these authorizations do not apply to Schedule II controlled substances.

Coronavirus Business Continuity Policy

As it pertains to the Business Continuity Policy, please refer to the email sent by Dr. Robert Nobles on March 19th.

Fun Things to Do With the Kids

Easter Eggs for Birds (PDF)

Adjusting to Remote Work

• Essential Work From Home Tips During the Coronavirus
• Staying Connected When Everyone's Remote
• How to Work Well When the Kids Are at Home Too
• Tips for Remote Work
• Supporting a Telecommuting Team

Extra Resource

Special Episode:  A Bit of Relief